This invention relates to a pharmaceutical combination comprising (a) a thirdgeneration EGFR tyrosine kinase inhibitorand (b) a cyclin D kinase 4/6 (CDK4/6) inhibitor, particularly for use in thetreatment of a cancer, particularly a lung cancer. Thisinvention also relates to uses of such a combination for the preparation of amedicament for the treatment of a cancer, methods oftreating a cancer in a subject in need thereof comprising administering tosaid subject a jointly therapeutically effective amount of saidcombination, pharmaceutical compositions comprising such combination andcommercial packages thereto.
